Journal
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
Volume 23, Issue 23, Pages -Publisher
MDPI
DOI: 10.3390/ijms232315056
Keywords
NSCLC; targeted therapy; drug resistance; molecular mechanisms; EGFR
Funding
- National Natural Science Foundation of China
- Natural Science Foundation Project of CQ CSTC
- Fundamental Research Funds for the Central Universities
- [82172888]
- [31571454]
- [cstc2020jcyj-msxmX0154]
- [2022CDJXY-004]
Ask authors/readers for more resources
Precision medicine has expanded treatment options for NSCLC patients through targeted therapy based on genetic and epigenetic cues. Antibodies and inhibitors that target critical gene-mediated signaling pathways have improved patient prognosis. However, resistance due to genetic alterations poses significant challenges in the treatment of metastatic NSCLC patients.
The advent of precision medicine has brought light to the treatment of non-small cell lung cancer (NSCLC), expanding the options for patients with advanced NSCLC by targeting therapy through genetic and epigenetic cues. Tumor driver genes in NSCLC patients have been uncovered one by one, including epidermal growth factor receptor (EGFR), mesenchymal lymphoma kinase (ALK), and receptor tyrosine kinase ROS proto-oncogene 1 (ROS1) mutants. Antibodies and inhibitors that target the critical gene-mediated signaling pathways that regulate tumor growth and development are anticipated to increase patient survival and quality of life. Targeted drugs continue to emerge, with as many as two dozen approved by the FDA, and chemotherapy and targeted therapy have significantly improved patient prognosis. However, resistance due to cancer drivers' genetic alterations has given rise to significant challenges in treating patients with metastatic NSCLC. Here, we summarized the main targeted therapeutic sites of NSCLC drugs and discussed their resistance mechanisms, aiming to provide new ideas for follow-up research and clues for the improvement of targeted drugs.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available